0.3998

2.09% +0.0082

Galmed Pharmaceuticals Ltd (GLMD)

Overview News Price History Why GLMD Down? Discussions Forecast Stock Split

Galmed Pharmaceuticals Ltd stock is currently priced at $0.3998, with a 24-hour trading volume of 12,069. It has seen a +2.09% increased in the last 24 hours and a +15.45% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.3845 pivot point. If it approaches the $0.402 resistance level, significant changes may occur.

Previous Close:

$0.3916

Open:

$0.3925

24h Volume:

12,069

Market Cap:

$2.35M

Revenue:

Net Income/Loss:

$-6.91M

P/E Ratio:

-0.0598

EPS:

-6.69

Net Cash Flow:

$-6.14M

1W Performance:

+9.80%

1M Performance:

+15.45%

6M Performance:

+6.61%

1Y Performance:

-91.40%

1D Range:

$0.376

$0.40

52W Range:

$0.26

$7.80

Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile

Name

Galmed Pharmaceuticals Ltd

Sector

Healthcare (1202)

Industry

Biotechnology (688)

Phone

972 3 693 8448

Address

16 Tiomkin Street, Tel Aviv

Employee

Twitter

@GalmedPharma

Next Earnings Date

2024-03-27

Latest SEC Filings

GLMD's Discussions on Twitter

Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-22-20	Downgrade	B. Riley FBR	Buy → Neutral
Feb-04-20	Initiated	Craig Hallum	Buy
Jan-30-20	Resumed	Cantor Fitzgerald	Overweight
Dec-02-19	Initiated	Canaccord Genuity	Buy
Dec-12-18	Initiated	B. Riley FBR	Buy
Aug-02-18	Reiterated	Maxim Group	Buy
Jul-13-18	Initiated	Stifel	Buy
Jul-12-18	Initiated	Cantor Fitzgerald	Overweight
Jun-12-18	Reiterated	H.C. Wainwright	Buy
Mar-15-18	Upgrade	Maxim Group	Hold → Buy
Feb-14-18	Downgrade	Maxim Group	Buy → Hold
Feb-12-18	Reiterated	H.C. Wainwright	Buy
Nov-15-17	Initiated	ROTH Capital	Buy
Aug-08-17	Reiterated	H.C. Wainwright	Buy
Jul-31-17	Reiterated	Maxim Group	Buy
Aug-01-16	Reiterated	Maxim Group	Buy
Jul-06-16	Resumed	ROTH Capital	Buy
Mar-28-16	Resumed	H.C. Wainwright	Buy
Jun-23-15	Initiated	H.C. Wainwright	Buy
May-06-15	Initiated	Sun Trust Rbsn Humphrey	Buy

View All

Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News

Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

Benzinga

Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

Benzinga

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

The Motley Fool

Gold Rises 1%; Hibbett Shares Spike Higher

Benzinga

Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Galmed Pharmaceuticals Ltd Stock (GLMD) Financials Data

Galmed Pharmaceuticals Ltd (GLMD) Net Income 2024

GLMD net income (TTM) was -$6.91 million for the quarter ending December 31, 2023, a +61.31% increase year-over-year.

Galmed Pharmaceuticals Ltd (GLMD) Cash Flow 2024

GLMD recorded a free cash flow (TTM) of -$6.14 million for the quarter ending December 31, 2023, a +66.84% increase year-over-year.

Galmed Pharmaceuticals Ltd (GLMD) Earnings per Share 2024

GLMD earnings per share (TTM) was -$3.26 for the quarter ending December 31, 2023, a +69.27% growth year-over-year.

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.